<DOC>
	<DOCNO>NCT01226771</DOCNO>
	<brief_summary>This randomize , open-label , parallel group , multicenter pilot study evaluate efficacy safety alternative dose ribavirin vs. standard care dose combination peginterferon alpha-2a interferon naïve patient chronic hepatitis c genotype 1 infection .</brief_summary>
	<brief_title>Ribavirin Loading Dose Priming Concentration Targeting HCV Genotype 1</brief_title>
	<detailed_description>The primary objective study demonstrate efficacy safety ( A ) 2 week high dose ribavirin ( `` loading '' , ≥26 mg/kg/day 14 day follow ≥13 mg/kg/day ) follow concentration target ( ≥ 2.5 mg/L ( 10.25 μmol/L ) 28 day initiation ribavirin therapy ) dose ribavirin vs. ( B ) 4 week ribavirin dose initiation PEG-interferon dosing ( `` priming '' , ≥13 mg/kg/day ) follow concentration target ( ≥ 2.5 mg/L ( 10.25 μmol/L ) 28 day initiation ribavirin therapy ) dose ribavirin combination peginterferon alpha-2a interferon naïve patient chronic hepatitis C ( CHC ) virus genotype 1 infection compare ( C ) standard-of-care dose ribavirin ( ≥13 mg/kg/day without monitor ribavirin concentration ) combination peginterferon alpha-2a .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Written inform consent Male female patient ≥18 year age Serologic evidence chronic hepatitis C infection antiHCV antibody test Serum HCVRNA ≥15 IU/mL . HCV genotype 1 infection confirm within past 2 year precede initiation test drug dosing . Compensated liver disease ( ChildPugh Grade A clinical classification ) Patients cirrhosis transition cirrhosis must abdominal ultrasound , CT scan , MRI scan without evidence hepatocellular carcinoma serum AFP ≤100 ng/mL within 2 month randomization Negative urine blood pregnancy test ( woman childbearing potential ) document within 24hour period prior first dose study drug All fertile male females receive ribavirin must use effective contraception treatment 4 month female patient / 7 month male patient end treatment Subject must weigh 45 105 kg screen Women ongoing pregnancy breast feed IFN/ peginterferon without ribavirin therapy previous time Therapy systemic antiviral , antineoplastic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) *6 month prior first dose study drug Any investigational drug ≤6 week prior first dose study drug . HCV genotype 2 , 3 , 4 , 5 , 6 , 7 infection . Positive test screen antiHAV IgM Ab , HBsAg , antiHBc IgM Ab , antiHIV Ab Evidence medical condition associate chronic liver disease HCV ( e.g. , hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure ) History evidence decompensated liver disease Neutrophil count &lt; 1500 cells/mm3 platelet count &lt; 90,000 cells/mm3 screen Serum creatinine level &gt; 2 mg/dl ( &gt; 124 µmol/L ) creatinine clearance ≤50 ml/minute screen Severe psychiatric disease , especially depression , judge treat physician . History severe seizure disorder current anticonvulsant use History immunologically mediate disease , severe chronic pulmonary disease associate functional limitation , severe cardiac disease , major organ transplantation evidence severe illness , malignancy , condition would make patient , opinion investigator , unsuitable study Thyroid dysfunction adequately control ( TSH T4 level normal range ) Evidence severe retinopathy ( e.g . CMV retinitis , macula degeneration ) clinically relevant ophthalmological disorder due diabetes mellitus hypertension Evidence drug abuse ( include excessive alcohol consumption ) accordance local therapeutic tradition . Inability unwillingness provide inform consent abide requirement study Male partner woman pregnant Ηemoglobin &lt; 12 g/dL woman &lt; 13 g/dL men screen . Any patient increase baseline risk anemia ( e.g . thalassemia major , spherocytosis , history GI bleeding , etc ) anemia would medically problematic coagulopathia . Patients document presumed coronary artery disease cerebrovascular disease enrol , judgment investigator , acute decrease hemoglobin 4 g/dL ( may see ribavirin therapy ) would welltolerated Evidence allergy PEGIFN ribavirin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>hepatitis V virus</keyword>
	<keyword>genotype 1</keyword>
	<keyword>ribavirin</keyword>
	<keyword>interferon</keyword>
	<keyword>Alternative ribavirin dose</keyword>
</DOC>